Evidence map›Paper›PMID 40038127›Full record

ArticleAnalytical and bioanalytical chemistry2025

Development of amyloid β (1-42) certified reference material NMIJ CRM 6210-a.

Kazumi Saikusa, Tomoya Kinumi, Megumi Kato

Abstract read
PubMed Publisher
In one paragraph

Article in Analytical and bioanalytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kazumi SaikusaNational Metrology Institute of Japan (NMIJ), National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Umezono, Tsukuba, Ibaraki, 305-8563, Japan. saikusa.kazumi@aist.go.jp.
Tomoya KinumiNational Metrology Institute of Japan (NMIJ), National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Umezono, Tsukuba, Ibaraki, 305-8563, Japan.
Megumi KatoNational Metrology Institute of Japan (NMIJ), National Institute of Advanced Industrial Science and Technology (AIST), 1-1-1 Umezono, Tsukuba, Ibaraki, 305-8563, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloid β is a well-known peptide biomarker for Alzheimer's disease. Various methods for amyloid β such as immunological assays have been reported. It is important to establish metrological traceability using a certified reference material (CRM) at the highest level in the calibration hierarchy to assess equivalence of measured values obtained from each method. Herein, we developed a CRM for amyloid β, named as NMIJ CRM 6210-a, with a concentration traceable to the International System of Units (SI). This CRM comprises a lyophilized synthetic peptide with a human amyloid β (1-42) sequence (hereafter, amyloid β) and includes oxidated, deamidated, and isomerized forms of amyloid β. Two certified values were assigned for the mass concentration of total amyloid β (a mixture of amyloid β and its oxidized, deamidated, and isomerized forms) and amyloid β, determined via amino acid analyses with two different hydrolysis methods with different liquid chromatography mass spectrometry methods coupled to isotope-dilution mass spectrometry on the reconstituted solution of the candidate material with (1.00

Indexed as

Amyloid beta-PeptidesPeptide FragmentsChromatography, LiquidHumansMass SpectrometryReference StandardsAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide FragmentsAmino acid analysisAmyloid βCertified reference materialIsotope-dilution mass spectrometryLyophilized form

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.